ACHE and Alzheimer disease: Among these, Galanthamine, which was approved in 2001 by the FDA for AD treatment, showed a strong AChE inhibitory activity (IC50 of 0.3–0.5 μM) [20], exerted by inhibiting substrate accommodation and hydrolysis in the active site of the enzyme [94].